Yet another round of financing
Yet another round of financingFINANCING ISSUE
Crossject has raised €5m through the issuance of convertible bonds. Management indicates that this financing round should meet funding requirements until the EUA is granted. We will incorporate this financing, considering the benefits of the additional cash and the potential for further dilution. However, due to the amount and nature of the issuance, the impact on our figures will be limited.
FACT
Crossject has announced the completion of a €5m fundraising.
ANALYSIS
Crossject has completed a €5m fundraising, fully subscribed by funds managed by Vatel Capital SA. The transaction involved a reserved issue of three tranches of convertible bonds, with annual cash interest rates between 7.5% and 9.5%, over a term of 3 to 5 years, and a fixed conversion price of €2.65 per share, representing a 9.8% premium over a 10-day VWAP closing.
This transaction could result in the issuance of up to 1,886,790 new ordinary shares, each with a par value of €0.10, potentially accounting for approximately 3.52% of the share capital on a non-diluted basis. Half of the funds will be allocated to the development and registration of ZEPIZURE, covering related operating costs in addition to R&D costs reimbursed by BARDA. The remaining funds will support other R&D activities, investments in manufacturing facilities, and general corporate needs, including the repayment of certain financial obligations.
According to management, this transaction is expected to secure financing needs until the EUA is granted. However, it is noteworthy that in September 2025, Crossject secured an additional €11.3m in R&D funding from BARDA. This suggests a cautious approach by the group, which may not be entirely reassuring regarding the anticipated EUA approval, but reflects management’s prudence.
IMPACT
We will incorporate the convertible bonds into our model, balancing the benefits of additional cash with the potential for increased dilution. Considering the size and features of the issuance, the impact on our figures will be minimal.
Crossject SA is a France-based company that designs and develops medical injection systems. The Company specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The Company's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance and comfort. Crossject's first ZENEO SUPERGENERIC product is expected to reach the market in the year 2015. The Company has industrial partnerships with Hirtenberger and Recipharm.
AlphaValue Corporate Services capitalise on the research and credit analysis expertise deployed by AlphaValue with major institutional investors at European level over the past nine years. The proprietary tools and processes enabling AlphaValue Corporate Services to establish a valuation and/or a credit risk assessment are identical to those used by AlphaValue to the benefit of its institutional clients. The only difference is the recognition that a company evaluation cannot be dissociated from the fact that the latter is paying for the service (AlphaValue Corporate Services), as opposed to the investor footing the bill (AlphaValue). AlphaValue’s research tools are characterised by the transparency of the valuation methodologies, their responsiveness to market data and by nine years’ experience of a universe numbering more than 450 European companies. Through its coverage and sector exhaustiveness, AlphaValue ranks alongside the major research houses in Europe and constitutes the only new entrant to the European space in the past decade. This significant presence is reflected in an unrivalled distribution capability via platforms commonly adopted by investors to access research: Factset, Bloomberg, Capital IQ and the numerous websites. AlphaValue is one the largest research contributors to these platforms, to the benefit of AlphaValue Corporate Services issuer clients. The AlphaValue Corporate Services analysts are AlphaValue’s sector specialists. Their robust knowledge of the business models in their sectors enables the rapid generation of incisive, relevant research and advantageous interaction with the management teams.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.